We have located links that may give you full text access.
Expanding the Use of HCV Infected Organs and the Challenge of Third-Party Payers.
American Journal of Transplantation 2020 January 23
Since the publication of the first two novel reports demonstrating the feasibility of using Hepatitis C virus nucleic acid test positive (HCV NAT+) organs into negative recipients1,2 , evidence regarding the safety of using HCV NAT+ organs have been mounting. However, the wide implementation of such a practice hinges on the ability to ensure timely delivery of direct acting antiviral (DAA) therapy after transplantation. To date, DAA coverage by third party payers for acute HCV infection cannot be guaranteed.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app